PL2376101T3 - Elektory beta-arestyny oraz ich kompozycje i sposoby stosowania - Google Patents

Elektory beta-arestyny oraz ich kompozycje i sposoby stosowania

Info

Publication number
PL2376101T3
PL2376101T3 PL09836520T PL09836520T PL2376101T3 PL 2376101 T3 PL2376101 T3 PL 2376101T3 PL 09836520 T PL09836520 T PL 09836520T PL 09836520 T PL09836520 T PL 09836520T PL 2376101 T3 PL2376101 T3 PL 2376101T3
Authority
PL
Poland
Prior art keywords
beta
compositions
methods
arrestin effectors
arrestin
Prior art date
Application number
PL09836520T
Other languages
English (en)
Inventor
Dennis Yamashita
Xiao-Tao Chen
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of PL2376101T3 publication Critical patent/PL2376101T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL09836520T 2008-12-29 2009-12-28 Elektory beta-arestyny oraz ich kompozycje i sposoby stosowania PL2376101T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14112608P 2008-12-29 2008-12-29
PCT/US2009/006719 WO2010077339A2 (en) 2008-12-29 2009-12-28 β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
EP09836520.8A EP2376101B1 (en) 2008-12-29 2009-12-28 Beta-arrestin effectors and compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
PL2376101T3 true PL2376101T3 (pl) 2016-03-31

Family

ID=42310455

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09836520T PL2376101T3 (pl) 2008-12-29 2009-12-28 Elektory beta-arestyny oraz ich kompozycje i sposoby stosowania

Country Status (16)

Country Link
US (7) US8486885B2 (pl)
EP (1) EP2376101B1 (pl)
JP (1) JP5647146B2 (pl)
CN (1) CN102333536B (pl)
AU (1) AU2009333883B2 (pl)
CA (1) CA2748340C (pl)
CY (1) CY1117184T1 (pl)
DK (1) DK2376101T3 (pl)
ES (1) ES2558629T3 (pl)
HR (1) HRP20151440T1 (pl)
HU (1) HUE026131T2 (pl)
NZ (1) NZ594302A (pl)
PL (1) PL2376101T3 (pl)
PT (1) PT2376101E (pl)
SI (1) SI2376101T1 (pl)
WO (1) WO2010077339A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5647146B2 (ja) * 2008-12-29 2014-12-24 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． β−アレスチンエフェクターおよび組成物およびその使用方法
EP2809337A4 (en) * 2012-01-31 2016-05-11 Trevena Inc SS ARRESTINE EFFECTORS AND COMPOSITIONS AND METHOD FOR THE APPLICATION THEREOF
JP2017506235A (ja) 2014-02-07 2017-03-02 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． ベータ−アレスチンエフェクターの結晶性および非晶質形態
CA2948858A1 (en) 2014-05-19 2015-11-26 Trevena, Inc. Synthesis of beta-arrestin effectors
CN104162146B (zh) * 2014-08-06 2016-12-07 中国人民解放军第二军医大学 β-抑制蛋白-1在制备预防或治疗心梗药物中的应用
WO2016196750A1 (en) * 2015-06-03 2016-12-08 Trevena, Inc. Beta-arrestin effectors and compositions and methods of use thereof
TWI776812B (zh) * 2016-06-02 2022-09-11 荷蘭商菲林公司 血管收縮素-1-受體拮抗劑
JOP20170133B1 (ar) * 2016-06-02 2022-03-14 Ferring Bv عوامل مضادة لمستقبل أنجيوتنسين-1
AR108906A1 (es) 2016-06-29 2018-10-10 Bristol Myers Squibb Co Heterociclos de biarilmetilo
US20210324005A1 (en) * 2020-04-21 2021-10-21 Trevena, Inc. Beta-Arrestin Effectors and Compositions and Methods of Use Thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3751404A (en) 1971-02-12 1973-08-07 Morton Norwich Products Inc L-prolyl-l-arginyl-l-volyl-l-tyrosyl-l-volyl-l-histidyl-l-prolyl-glycine
DE2360794C2 (de) 1973-12-06 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung von Peptiden
US3932624A (en) * 1974-06-17 1976-01-13 Morton-Norwich Products, Inc. Method for prolonging the inhibitory effect of saralasin on angiotensin II
JPS5825980B2 (ja) * 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4298523A (en) 1980-06-17 1981-11-03 Ortho Pharmaceutical Corporation Methods and compositions for preparation of H-ARG-X-Z-Y-TYR-R
US4547489A (en) * 1984-06-11 1985-10-15 Ortho Pharmaceutical Corporation Conformationally restricted thymopentin-like compounds
US5182264A (en) * 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
EP0358418B1 (en) 1988-09-05 1992-12-16 Sankyo Company Limited Cyclic peptide, its preparation and its use in the treatment of cardiovascular disorders
GB8822483D0 (en) * 1988-09-24 1988-10-26 Medical Res Council Developments relating to mas oncogene
US5401629A (en) * 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
CA2090401A1 (en) 1990-08-27 1992-02-28 Deborah A. Rathjen Method of treating viral infection
EP0498361A3 (en) * 1991-02-06 1992-09-02 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
DK0730465T3 (da) 1993-09-24 2002-04-08 Univ Southern California Anvendelse af angiotensin III og analoger dertil til vævsreparation
US5889020A (en) * 1994-02-08 1999-03-30 Ciba Vision Corporation Treatment of normotensive glaucoma with angiotensin II antagonists
US5958884A (en) 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
AU755225B2 (en) 1997-12-12 2002-12-05 University Of Southern California Wound healing compositions
US20040214836A1 (en) * 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20050202029A1 (en) * 2003-10-03 2005-09-15 The Board Of Trustees Of The Leland Stanford Junior University Family of cystatin-related chemoattractant proteins
US20070286863A1 (en) * 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
GB0705488D0 (en) * 2007-03-22 2007-05-02 Isis Innovation Treatment of inflammation and/or endotoxic shock
CA2692372A1 (en) 2007-06-27 2008-12-31 Clayton Corporation Dispensing system and method of use
EP2279009A4 (en) 2008-05-05 2011-09-21 Univ Rochester METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE
US8038992B2 (en) * 2008-05-10 2011-10-18 The Board Of Trustees Of The Leland Stanford Junior University Target for regulating multiple sclerosis
US20100092974A1 (en) * 2008-08-15 2010-04-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for modulators of ccrl2
JP5647146B2 (ja) 2008-12-29 2014-12-24 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． β−アレスチンエフェクターおよび組成物およびその使用方法
ES2528948T3 (es) 2009-09-21 2015-02-13 Chemocentryx, Inc. Derivados de pirrolidinona carboxamida como moduladores de quemerina-R (ChemR23)
BR112012032796A2 (pt) 2010-06-24 2016-11-22 Arisaph Pharmaceuticals Inc miméticos niacina, e os métodos de utilização dos mesmos
WO2012150890A1 (en) 2011-05-02 2012-11-08 Lipidor Ab Antibacterial composition

Also Published As

Publication number Publication date
CY1117184T1 (el) 2017-04-05
HUE026131T2 (en) 2016-05-30
US20130274176A1 (en) 2013-10-17
SI2376101T1 (sl) 2016-02-29
US8993511B2 (en) 2015-03-31
JP2012514033A (ja) 2012-06-21
US8796204B2 (en) 2014-08-05
CA2748340A1 (en) 2010-07-08
EP2376101B1 (en) 2015-12-02
HRP20151440T1 (hr) 2016-01-29
PT2376101E (pt) 2016-02-04
ES2558629T3 (es) 2016-02-05
EP2376101A2 (en) 2011-10-19
WO2010077339A3 (en) 2011-02-24
AU2009333883A1 (en) 2011-08-18
US20140005114A1 (en) 2014-01-02
JP5647146B2 (ja) 2014-12-24
CN102333536B (zh) 2014-08-13
US9534017B2 (en) 2017-01-03
US8809260B2 (en) 2014-08-19
US8486885B2 (en) 2013-07-16
CN102333536A (zh) 2012-01-25
CA2748340C (en) 2017-01-24
WO2010077339A2 (en) 2010-07-08
AU2009333883B2 (en) 2015-05-21
US20150166604A1 (en) 2015-06-18
US20140357562A1 (en) 2014-12-04
HK1162955A1 (zh) 2012-09-07
EP2376101A4 (en) 2012-11-28
US20170298094A1 (en) 2017-10-19
NZ594302A (en) 2013-07-26
DK2376101T3 (en) 2016-01-18
US20100184701A1 (en) 2010-07-22
US20140336123A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
ZA201004914B (en) Compositions and methods of detecting tiabs
PL2376101T3 (pl) Elektory beta-arestyny oraz ich kompozycje i sposoby stosowania
IL208946A0 (en) Immunomodulating compositions and methods of use thereof
ZA201008483B (en) Diazacarbazoles and methods of use
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
SI2320911T1 (sl) Vazokonstrikcijski sestavki in metode uporabe
EP2334185A4 (en) COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
IL205977A0 (en) 5-anilinoimidazopyridines and methods of use
PL2346327T3 (pl) Kompozycje biobójcze i sposoby stosowania
EP2231665A4 (en) NEW COMPOSITIONS AND METHODS OF USE
IL208403A0 (en) Compositions and use of epas1 inhibitors
EP2421901A4 (en) COMPOSITION CONTAINING THE HC HA COMPLEX AND METHODS OF USE THEREOF
IL206125A0 (en) Azaindolizines and methods of use
IL209548A0 (en) Diazacarbazoles and methods of use
EP2271750A4 (en) URICASE COMPOSITIONS AND METHODS OF USE
PL2179657T3 (pl) Kompozycje z efuzją gazu i sposób ich wytwarzania
EP2142926A4 (en) COMPOSITIONS AND METHODS OF DETECTION
ZA201102207B (en) Cinnamandehyde-allicin compositions and their method of use
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
EP2416796A4 (en) Modified dnase compositions and methods of use thereof
ZA201004894B (en) Nuctraceutical composition and methods of use
GB201021639D0 (en) Nutritive compositions and methods of using same
EP2381950A4 (en) COMPOSITIONS AND METHOD FOR THEIR USE
PL2366013T3 (pl) Kompozycje do prania i sposoby ich zastosowania
ZA201004893B (en) Nuctraceutical composition and methods of use